Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.57 |
| ▸ | SUV39H1 | O43463 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | EP300 | Q09472 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.43 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verticillin A SCHEMBL18294765 | 1.00 | KMT2A (1.00) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin A SCHEMBL19275238 | 1.00 | KMT2A (1.00) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin A SCHEMBL15791200 | 1.00 | KMT2A (1.00) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin A SCHEMBL29623144 | 1.00 | KMT2A (1.00) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Gliocladine B SCHEMBL30076641 | 0.96 | KMT2A (0.91) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin A SCHEMBL29623110 | 0.96 | KMT2A (0.91) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Gliocladine A SCHEMBL29794217 | 0.96 | KMT2A (0.91) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin B SCHEMBL17975438 | 0.91 | KMT2A (0.82) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin B SCHEMBL5894069 | 0.91 | KMT2A (0.82) | KMT2AEHMT2SUV39H1HIF1AEP300 | |
| Verticillin B SCHEMBL21497282 | 0.91 | KMT2A (0.82) | KMT2AEHMT2SUV39H1HIF1AEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3847282-A1 | BIOMARKERS FOR CANCER THERAPY | The Council of the Queensland Institute of Medical Research (AU) | 2021-07-14 | — | — | EP | claimed |
| CN-105596347-B | Verticillin A and application in medicine preparation is combined with TRAIL | 浙江大学 | 2018-04-20 | — | — | CN | claimed |
| WO-2016086118-A1 | GLYCEROL-BASED POLYCARBONATES | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-06-02 | — | — | WO | claimed |
| CN-105596347-A | Application of verticillin A and combination of verticillin A and TRAIL in medicine preparation | UNIV ZHEJIANG | 2016-05-25 | — | — | CN | claimed |
| US-20140161785-A1 | Verticillin A Inhibition of Histone Methyltransferases | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-06-12 | — | — | US | claimed |
| WO-2012161799-A1 | EPIDITHIODIOXOPIPERAZINES AND USES THEREOF IN TREATING CANCER | GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC (US) | 2012-11-29 | — | — | WO | claimed |
| US-20120219568-A1 | EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER | ZHEJIANG UNIVERSITY | 2012-08-30 | — | — | US | claimed |
| CN-1285598-C | Method for preparing verticillium bacteria A and application | UNIV ZHEJIANG (CN) | 2006-11-22 | — | — | CN | claimed |
| US-12448398-B2 | Semi-synthetic analogues of epipolythiodioxopiperazine alkaloids | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-11819554-B2 | Compositions and methods for modulating FMR1 expression | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230015276-A1 | METHODS AND COMPOSITIONS TO INCREASE SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3349749-B1 | COMPOSITIONS AND METHODS FOR MODULATING FMR1 EXPRESSION | UNIV MASSACHUSETTS (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220235072-A1 | SEMI-SYNTHETIC ANALOGUES OF EPIPOLYTHIODIOXOPIPERAZINE ALKALOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-28 | — | — | US | disclosed |
| US-11390885-B2 | Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-07-19 | — | — | US | disclosed |
| CN-1285598-C | Method for preparing verticillium bacteria A and application | UNIV ZHEJIANG (CN) | 2006-11-22 | — | — | CN | disclosed |
| US-7112425-B2 | Polynucleotides and polypeptides coded by said polynucleotides involved in the synthesis of diketopiperazine derivatives | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2006-09-26 | — | — | US | disclosed |
| US-20060051837-A1 | Polynucleotides and polypeptides coded by said polynucleotides involved in the synthesis of diketopiperazine derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-03-09 | — | — | US | disclosed |
| CN-1687077-A | Method for preparing verticillium bacteria A and application | UNIV ZHEJIANG (CN) | 2005-10-26 | — | — | CN | disclosed |
| CN-1687077-A | Method for preparing verticillium bacteria A and application | UNIV ZHEJIANG (CN) | 2005-10-26 | — | — | CN | disclosed |
| CN-1668639-A | Polynucleotides involved in synthesis of diketopiperazine derivatives and polypeptides encoded by said polynucleotides | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2005-09-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161785-A1 | Verticillin A Inhibition of Histone Methyltransferases | SUV39H2, SUV39H1, NSD1 | KMT2A 16/4885EHMT2 7/4885SUV39H1 2/4885 |
| US-20120219568-A1 | EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER | TOP2A, EI24, BAD | KMT2A 3006/4885EHMT2 2639/4885SUV39H1 1296/4885 |
| US-12448398-B2 | Semi-synthetic analogues of epipolythiodioxopiperazine alkaloids | EHMT1, EHMT2, KMT5A | KMT2A 7/4885EHMT2 2/4885SUV39H1 8/4885 |
| US-20220235072-A1 | SEMI-SYNTHETIC ANALOGUES OF EPIPOLYTHIODIOXOPIPERAZINE ALKALOIDS | EHMT1, EHMT2, KMT5A | KMT2A 7/4885EHMT2 2/4885SUV39H1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.